General Finance Corp's Series C Cumulative Redeemable Perpetual Preferred Stock Ex-Dividend Reminder - 10/28/13

On 10/28/13, General Finance Corp's 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock (GFNCP) will trade ex-dividend, for its quarterly dividend of $2.30, payable on 10/31/13. As a percentage of GFNCP's recent share price of $100.44, this dividend works out to approximately 2.29%, so look for shares of GFNCP to trade 2.29% lower — all else being equal — when GFNCP shares open for trading on 10/28/13. On an annualized basis, the current yield is approximately 9.16%, which compares to an average yield of 9.46% in the "Business Services & Equipment" preferred stock category, according to Preferred Stock Channel.

START SLIDESHOW:
Click here to learn which S.A.F.E. dividend stocks also have preferred shares that should be on your radar screen »

As of last close, GFNCP was trading at a 0.44% premium to its liquidation preference amount.The chart below shows the one year performance of GFNCP shares, versus GFN:

Performance Comparison Chart

Below is a dividend history chart for GFNCP, showing historical dividends prior to the most recent $2.30 on General Finance Corp's 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock :

GFNCP+Dividend+History+Chart

In Thursday trading, General Finance Corp's 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock ( GFNCP) is currently trading flat on the day, while the common shares ( GFN) are off about 1.2%.

null

More from Stocks

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug